- Correction
- Open access
- Published:
Correction to: Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis
BMC Pulmonary Medicine volume 20, Article number: 131 (2020)
The Original Article was published on 31 January 2020
Correction to: BMC Pulm Med (2020) 20:27
https://doi.org/10.1186/s12890-020-1060-y
Following publication of the original article [1], the authors have flagged that there is an error in Fig. 3.
Namely, asterisks indicating significant difference are missing in the figure.
Please see the correct version of Fig. 3 in this correction article.
The authors apologize for any inconvenience caused.
Relative change in SP-A, SP-D, and KL-6 levels in the initial 3 and 6 months in the stable and progression groups. Changes in SP-A at 3 and 6 months, SP-D at 6 months, and KL-6 at 3 and 6 months were significantly smaller in the stable group than the progression group (*p < 0.05). Data were analyzed by Mann-Whitney U test. Horizontal line indicates median concentration. The upper and lower limits of the box indicate the inter-quartile range
Reference
Yoshikawa T, et al. Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis. BMC Pulm Med. 2020;20:27. https://doi.org/10.1186/s12890-020-1060-y.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Yoshikawa, T., Otsuka, M., Chiba, H. et al. Correction to: Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis. BMC Pulm Med 20, 131 (2020). https://doi.org/10.1186/s12890-020-1118-x
Published:
DOI: https://doi.org/10.1186/s12890-020-1118-x